Gamida Cell signs collaboration agreement with Biologics Delivery Systems

Gamida Cell has signed a collaboration agreement with Biologics Delivery Systems Group, Cordis. Under the terms of the agreement, Biologics Delivery Systems will supply catheters for the upcoming Phase I/II clinical trial of Gamida Cell's CardioCure product for the treatment of post-myocardial infarction (MI) patients. CardioCure is a proprietary ex-vivo expanded autologous bone marrow product. The randomized, controlled multi-center Phase I/II clinical trial, due to start in the fourth quarter of 2008 in Israel, will evaluate the safety and efficacy of Gamida Cell's CardioCure in 48 post-MI patients. CardioCure will be injected directly into the myocardium using the latest generation of Biologics Delivery Systems's Noga cardiac navigation system and MyoStar injection catheter. Pre-clinical results demonstrate that CardioCure... [read full story]